2023 - Research.com Immunology in United Kingdom Leader Award
2010 - Member of the National Academy of Sciences
2007 - Fellow of the Royal Society, United Kingdom
His primary areas of investigation include Rheumatoid arthritis, Immunology, Arthritis, Tumor necrosis factor alpha and Cytokine. His Rheumatoid arthritis study improves the overall literature in Internal medicine. His Internal medicine research includes themes of Gastroenterology, Placebo and Surgery.
His studies link Alpha with Immunology. His Tumor necrosis factor alpha research is multidisciplinary, relying on both Synovial Cell, Synovial membrane, Interleukin and Antibody, Monoclonal antibody. His work carried out in the field of Cytokine brings together such families of science as Endocrinology, Synovial fluid, Molecular biology, Proinflammatory cytokine and Pharmacology.
Ravinder N. Maini mainly investigates Immunology, Rheumatoid arthritis, Antibody, Tumor necrosis factor alpha and Arthritis. His Immunology study which covers Disease that intersects with Transplantation and Clinical trial. His Rheumatoid arthritis study introduces a deeper knowledge of Internal medicine.
The various areas that he examines in his Antibody study include Gene and Antigen. His Tumor necrosis factor alpha research incorporates themes from Inflammation, Proinflammatory cytokine, Pathology, Interleukin and Pharmacology. His studies deal with areas such as Alpha and Immunotherapy as well as Arthritis.
Immunology, Rheumatoid arthritis, Internal medicine, Tumor necrosis factor alpha and Infliximab are his primary areas of study. His Immunology study frequently draws connections to other fields, such as Disease. Ravinder N. Maini combines subjects such as Methotrexate, Cytokine, Arthritis, Combination therapy and Necrosis with his study of Rheumatoid arthritis.
His Internal medicine study combines topics in areas such as Gastroenterology and MEDLINE. His biological study spans a wide range of topics, including Inflammation, Proinflammatory cytokine and Complex disease. In his study, Immunotherapy, Signs and symptoms, Adalimumab and Route of administration is inextricably linked to Etanercept, which falls within the broad field of Infliximab.
Ravinder N. Maini mostly deals with Rheumatoid arthritis, Tumor necrosis factor alpha, Arthritis, Infliximab and Immunology. Rheumatoid arthritis is a subfield of Internal medicine that Ravinder N. Maini tackles. Ravinder N. Maini usually deals with Internal medicine and limits it to topics linked to Surgery and Gastroenterology.
His study in Tumor necrosis factor alpha is interdisciplinary in nature, drawing from both Inflammation, Sustained remission and Cytokine. His Immunology study incorporates themes from Angiogenesis and Disease. The Antibody study combines topics in areas such as Chemokine and Systemic administration, In vivo.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
P E Lipsky;D M van der Heijde;E W St Clair;D E Furst.
The New England Journal of Medicine (2000)
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
R Maini;E W St Clair;F Breedveld;D Furst.
The Lancet (1999)
ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Marc Feldmann;Fionula M. Brennan;Ravinder N. Maini.
Annual Review of Immunology (1996)
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
M J Elliott;R N Maini;M Feldmann;J R Kalden.
The Lancet (1994)
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Ravinder N. Maini;Ferdinand C. Breedveld;Joachim R. Kalden;Josef S. Smolen.
Arthritis & Rheumatism (1998)
Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.
Claudio Vitali;Stefano Bombardieri;Haralampos M. Moutsopoulos;Genesio Balestrieri.
Arthritis & Rheumatism (1993)
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
Marc Feldmann;Ravinder N. Maini.
Annual Review of Immunology (2001)
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial
E William St Clair;Désirée M F M van der Heijde;Josef S Smolen;Ravinder N Maini.
Arthritis & Rheumatism (2004)
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha
M J Elliott;R N Maini;M Feldmann;A Long-Fox.
Arthritis & Rheumatism (1993)
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.
Richard O. Williams;Marc Feldmann;Ravinder N. Maini.
Proceedings of the National Academy of Sciences of the United States of America (1992)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: